COMMON STOCK PURCHASE WARRANT To Purchase 100,000 Shares of Common Stock of The Immune Response CorporationSecurity Agreement • November 14th, 2003 • Immune Response Corp • Biological products, (no disgnostic substances)
Contract Type FiledNovember 14th, 2003 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT CERTIFIES that, for value received, Cardinal Securities, LLC (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 10, 2003 (the “Initial Exercise Date”) and on or prior to the close of business on October 10, 2008 (the “Termination Date”) but not thereafter, to subscribe for and purchase from The Immune Response Corporation, a corporation incorporated in the State of Delaware (the “Company”), up to 100,000 shares (the “Warrant Shares”) of Common Stock, of the Company (the “Common Stock”). The purchase price of one share of Common Stock (the “Exercise Price”) under this Warrant shall be $3.32, subject to adjustment hereunder. The Exercise Price and the number of Warrant Shares for which the Warrant is exercisable shall be subject to adjustment as provided herein. Capitalized terms used and not otherwise defined herein shall have the meanings set
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 14th, 2003 • Immune Response Corp • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 14th, 2003 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of October 10, 2003, among The Immune Response Corporation, a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”); and
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 14th, 2003 • Immune Response Corp • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 14th, 2003 Company Industry JurisdictionThis Registration Rights Agreement (this “Agreement”) is made and entered into as of October 10, 2003, by and among The Immune Response Corporation, a Delaware corporation (the “Company”), and the investors signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).